1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
InBody Co., Ltd.

InBody Co., Ltd.

KKRX:041830
47,050.00
KRW
-1,200.00
(-2.49%)
3,076.73EPS
8.85P/E
368.22BMarket Cap
Nov 16Next Earn
InBody Co., Ltd.
KRX:041830
(Korea Stock Exchange)

Recent

price

47,050.00

P/E

ratio

8.85

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
1,800.91
2,318.49
2,443.94
2,702.11
3,593.63
5,066.36
5,866.33
6,901.67
7,390.09
8,778.64
8,163.49
10,582.75
12,283.4
13,076.88
15,774.69
18,504.92
19,253.41
Revenue per Share
385
406.59
415
455
652
1,272
1,248
1,430
1,459
1,532
1,335
2,613
2,596
2,819
2,557
2,423
3,117.58
Basic EPS, GAAP
231.63
193.33
191.38
-174.23
634.22
266.65
722.41
961.75
-1,723.28
1,570.1
2,025.66
1,421.45
1,873.33
2,383.05
1,622.11
2,242.92
2,392.93
Free Cash Flow per Basic Share
39.81
40
40.05
40
39.98
60.02
80.01
100.75
120
121.22
141.92
140.02
200.01
300
351.76
398.91
- -
Dividend per Share
2,668.12
3,073.21
3,389.09
3,787.55
4,377.12
5,606.39
6,780.37
7,897.32
9,234.09
10,501.72
11,519.66
14,104.32
16,524.35
19,096.39
21,471.41
23,823.96
24,633.65
Book Value per Share
2,663.39
2,966.86
3,220.83
3,622.6
4,215.12
5,479.64
6,655.93
7,785.16
9,149.18
10,444.76
11,463.82
14,002.78
16,395.66
19,002.62
21,311.68
23,685.05
24,501.51
Tangible Book Value per Share
14
14
14
14
14
14
14
14
13
13
13
13
13
13
13
13
13
Basic Weighted Avg Shares
24,399
31,561
33,230
36,787
48,940
68,949
79,848
93,254
99,635
117,059
107,122
137,837
160,004
170,351
204,465
233,948
246,809
Sales/Revenue/Turnover
16.54
15.8
15.05
17.67
20.63
29.02
27.6
26.7
23.76
23.6
17.83
26.01
25.44
22.51
17.97
15.71
17.33
Operating Margin (%)
304
477
574
922
1,109
1,369
1,748
1,751
2,017
3,999
4,507
4,436
5,374
5,961
7,074
8,611
9,008
Depreciation Expense
5,216
5,535
5,643
6,194
8,879
17,311
16,987
19,322
19,671
20,428
17,518
34,033
33,816
36,723
33,143
30,633
39,964
Net Income, GAAP
- -
3.78
6.16
12.2
16.75
16.64
18.36
17.42
20.48
27.69
15.07
13.61
20.39
18.02
25.41
22.33
18.72
Effective Tax Rate (%)
21.38
17.54
16.98
16.84
18.14
25.11
21.27
20.72
19.74
17.45
16.35
24.69
21.13
21.56
16.21
13.09
16.19
Profit Margin (%)
24,703
30,034
31,916
29,795
37,075
48,191
60,227
70,148
49,591
63,190
73,238
93,857
116,285
131,513
145,551
180,275
186,794
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
2,561
2,810
1,831
4,301
3,636
5,097
4,986
3,732
LT Debt
36,320
42,145
46,134
51,558
59,610
76,350
92,333
106,516
124,532
139,830
150,182
183,782
216,039
249,835
273,905
319,789
330,553
Total Equity
- -
12.76
10.76
11.7
14.97
23.94
20.91
20.4
15.95
14.49
10.62
17.69
15.32
12.83
10
9.13
11.04
Return on Invested Capital (%)
- -
13.82
12.78
12.68
15.97
25.46
20.14
19.42
17.21
15.27
11.74
19.95
16.53
15.53
12.58
10.34
13.17
Return on Capital (%)
15.42
14.16
12.83
12.68
15.98
25.48
20.15
19.44
17.04
15.47
12.09
20.39
16.95
15.83
12.7
10.37
13.29
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
4,751
5,357
4,752
LT Borrowings
- -
- -
- -
LT Finance Leases
4,781
4,986
3,732
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
13
13
Market Capitalization
356,623
436,933
368,225

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
176,152
213,155
230,256
Cash, Cash Equivalents & STI
101,503
138,776
147,102
Accounts Receivable, Net
28,805
29,824
30,996
Inventories
37,655
37,512
41,927
Total Current Liabilities
28,527
32,880
43,462
Payables & Accruals
- -
- -
- -
ST Debt
4,751
5,357
4,752
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.48%
16.39%
16.75%
Free Cash Flow
-20.76%
6.25%
34.87%
Net Income, GAAP
8.82%
16.98%
-7.57%
Sales/Revenue/Turnover
13.41%
17.13%
14.42%
Total Cash Common Dividend
21.04%
23.61%
10.61%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
48,429
50,243
50,720
55,073
204,465
2025
55,584
56,170
59,798
62,397
233,948
2026
68,445
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
675
638
571
677.4
2,557
2025
555
610.87
790.64
480.87
2,423
2026
1,224.25
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
351.76
2025
- -
- -
- -
- -
398.91
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
Medtronic plc. (NYSE:MDT)
Business
InBody Co., Ltd. manufactures and sells advanced electronic medical devices specializing in body composition analyzers. The company’s core products include body composition analyzers designed for clinical, sports, fitness, and home use; automatic sphygmomanometers (blood pressure monitors); stadiometers (height meters); body water analyzers; and body composition management software under the brands InBody and Lookin'Body. Its products serve diverse applications such as bariatrics, cardiology, diabetes management, frailty and aging assessment, ICU monitoring, lymphedema, nephrology, nutrition, oncology, sports medicine, rehabilitation, and physical therapy. InBody’s technology is validated by medical standards including FDA approval and is widely utilized by hospitals, clinics, fitness centers, and individual consumers globally. Founded in 1996 in Seoul, South Korea, the company operates through more than a dozen international subsidiaries including newly established units in North America and Malaysia, supporting its global reach in over 110 countries. Recent strategic initiatives include the launch of LookinBodyWeb, a cloud-based data software platform for body composition data management, and the introduction of the portable InBody270 device to facilitate professional on-the-go analysis. In 2025, InBody expanded its medical services division by establishing InBody BWA Inc. in North America with a focus on research-grade body water analysis and remote patient monitoring, aiming to integrate with healthcare insurance frameworks and expand its healthcare service offerings beyond devices. The company pursues strategic growth through direct distributor management and local sales strategies to stabilize and deepen market penetration, while maintaining a commitment to data-driven healthcare insights and service innovation. InBody continues evolving its business from a device manufacturer to a healthcare service provider by leveraging its extensive data accumulation of over 100 million data points to enhance remote health monitoring and community health integration. This transition is complemented by strong leadership emphasizing international market development, product quality, and organizational culture that encourages innovation and direct responsiveness to global market demands. The company remains headquartered in Seoul’s Gangnam district with approximately 1,100 employees worldwide. It is publicly listed on the KOSDAQ under ticker 041830.KQ. Overall, InBody operates within the healthcare equipment industry, focusing on body composition analysis technologies and expanding into medical and health data services to address broad medical and consumer health needs worldwide. Its recent expansions into cloud software, new device launches, and health service ecosystems mark significant advancements in its competitive positioning and strategic direction.